A carregar...
Long-responders to anti-HER2 therapies: A case report and review of the literature
Since the introduction of targeted therapies, prognosis in human epidermal growth factor receptor (HER) 2-positive metastatic breast cancer (MBC) has radically changed. The addition of Pertuzumab to Trastuzumab and standard chemotherapy has further increased patients' overall survival (OS). How...
Na minha lista:
| Publicado no: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5769304/ https://ncbi.nlm.nih.gov/pubmed/29387408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1495 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|